Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Use of Dual Immunomodulatory and Anti-microbial Probiotic (SALI-10) to Mitigate Osteoradio Necrosis and Dental Toxicity Post-radiation for Head and Neck Cancer (DIAMOND): Phase III Randomized Controlled Trial

NCT07883005 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT07883005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07883005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Use of Dual Immunomodulatory and Anti-microbial Probiotic (SALI-10) to Mitigate Osteoradio Necrosis and Dental Toxicity Post-radiation for Head and Neck Cancer (DIAMOND): Phase III Randomized Controlled Trial
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 1, 2031
Enrollment
288 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer